Dare Bioscience has received a grant from the Bill & Melinda Gates Foundation of $750,000 to fund activities related to bacteria-based live biotherapeutic product development. Dare previously received a grant of approximately $585,000 from the foundation for development of a hydrogel formulation for delivery of live biotherapeutics to support vaginal health in November 2022. The additional grant is intended to cover the costs of Dare personnel to gather and analyze data on the global bacterial biologic supply chain to help the foundation identify potential Contract Manufacturing Organization partners for manufacturing clinical and commercial supplies of bacteria-based biotherapeutic products.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DARE:
- Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
- Dare Bioscience achieves technological proof of concept for DARE-LARC1
- Dare Bioscience secures $12M in royalty-backed investment structure
- Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
- Dare Bioscience announces PK, exploratory efficacy results from DARE-PDM1 study
